【摘要】 目的探讨表皮生长因子受体(EGFR)突变型转移性非小细胞肺癌的靶向治疗疗效及安全性。方法选取80例EGFR突变型转移性非小细胞肺癌患者为研究对象,根据治疗方法的不同将患者分为观察组和对照组,每组各40例。对照组采用放射治疗,观察组采用表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI)吉非替尼联合放疗治疗,随访5~25个月,比较两组患者治疗4周后的疗效、治疗过程中的不良反应及随访结束时的生存情况。结果治疗4周后,观察组患者的治疗有效率和疾病控制率高于对照组(57.5%vs 35.0%,82.5%vs62.5%),差异均有统计学意义(P<0.05)。两组患者的不良反应均以1~2级为主,观察组患者的不良反应发生率为90.0%(36/40),与对照组的85.0%(34/40)比较,差异无统计学意义(P>0.05)。观察组与对照组患者的中位生存时间分别为15.2个月(95%CI:12.357~18.697)和12.1个月(95%CI:9.354~15.652),差异有统计学意义(χ~2=5.026,P=0.025)。结论对于EGFR突变型转移性非小细胞肺癌,EGFR-TKI靶向治疗可以提高疗效,延长患者的生存时间。更多还原

【Abstract】 Objective To evaluate the efficacy and safety of targeted therapy in the treatment of metastatic non-small cell lung cancer(NSCLC) with EGFR mutation. Method 80 patients of metastatic NSCLC with EGFR mutation were enrolled in the study, and were administered with radiotherapy(control group, n=40) or EGFR-TKI(gefitinib) combined with radiotherapy(study group, n=40), after a follow up period of 5-25 months, the curative effect, adverse reactions during the treatment and the survival of patients at the end of follow-up were compared between the two groups after 4weeks of treatment. Result After 4 weeks of treatment, the response rate of the study group(57.5% vs 35.0%) and disease control rate(82.5% vs 62.5%) were significantly higher than that of the control group, with statistically significant difference observed(P<0.05). The adverse reactions of the two groups were mainly grade I-II, and the incidence of adverse reactions in study group was 90.0%(36/40), compared with 85.0%(34/40) in control group, the difference was of no significant difference(P>0.05). The median survival time of the study group and the control group were 15.2 months(95%CI: 12.357-18.697) and 12.1 months(95%CI: 9.354-15.652) respectively, and were significantly different between the two groups(χ~2=5.026, P=0.025). Conclusion In the treatment of NSCLC with EGFR mutation, EGFR-TKI targeted therapy may improve the efficacy and prolong survival time for patients.更多还原